Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis
Copyright © 2021 by the American Society of Nephrology..
Background: Patients with ESKD on maintenance dialysis receive dialysis in common spaces with other patients and have a higher risk of severe SARS-CoV-2 infections. They may have persistently or intermittently positive SARS-CoV-2 RT-PCR tests after infection. We describe the clinical course of SARS-CoV-2 infection and the serologic response in a convenience sample of patients with ESKD to understand the duration of infectivity.
Methods: From August to November 2020, we enrolled patients on maintenance dialysis with SARS-CoV-2 infections from outpatient dialysis facilities in Atlanta, Georgia. We followed participants for approximately 42 days. We assessed COVID-19 symptoms and collected specimens. Oropharyngeal (OP), anterior nasal (AN), and saliva (SA) specimens were tested for the presence of SARS-CoV-2 RNA, using RT-PCR, and sent for viral culture. Serology, including neutralizing antibodies, was measured in blood specimens.
Results: Fifteen participants, with a median age of 58 (range, 37‒77) years, were enrolled. Median duration of RT-PCR positivity from diagnosis was 18 days (interquartile range [IQR], 8‒24 days). Ten participants had at least one, for a total of 41, positive RT-PCR specimens ≥10 days after symptoms onset. Of these 41 specimens, 21 underwent viral culture; one (5%) was positive 14 days after symptom onset. Thirteen participants developed SARS-CoV-2-specific antibodies, 11 of which included neutralizing antibodies. RT-PCRs remained positive after seroconversion in eight participants and after detection of neutralizing antibodies in four participants; however, all of these samples were culture negative.
Conclusions: Patients with ESKD on maintenance dialysis remained persistently and intermittently SARS-CoV-2-RT-PCR positive. However, of the 15 participants, only one had infectious virus, on day 14 after symptom onset. Most participants mounted an antibody response, including neutralizing antibodies. Participants continued having RT-PCR-positive results in the presence of SARS-CoV-2-specific antibodies, but without replication-competent virus detected.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Kidney360 - 2(2021), 12 vom: 30. Dez., Seite 1917-1927 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bardossy, Ana Cecilia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2022 Date Revised 16.02.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.34067/KID.0004372021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339490470 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339490470 | ||
| 003 | DE-627 | ||
| 005 | 20231226003020.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.34067/KID.0004372021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339490470 | ||
| 035 | |a (NLM)35419540 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bardossy, Ana Cecilia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2022 | ||
| 500 | |a Date Revised 16.02.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by the American Society of Nephrology. | ||
| 520 | |a Background: Patients with ESKD on maintenance dialysis receive dialysis in common spaces with other patients and have a higher risk of severe SARS-CoV-2 infections. They may have persistently or intermittently positive SARS-CoV-2 RT-PCR tests after infection. We describe the clinical course of SARS-CoV-2 infection and the serologic response in a convenience sample of patients with ESKD to understand the duration of infectivity | ||
| 520 | |a Methods: From August to November 2020, we enrolled patients on maintenance dialysis with SARS-CoV-2 infections from outpatient dialysis facilities in Atlanta, Georgia. We followed participants for approximately 42 days. We assessed COVID-19 symptoms and collected specimens. Oropharyngeal (OP), anterior nasal (AN), and saliva (SA) specimens were tested for the presence of SARS-CoV-2 RNA, using RT-PCR, and sent for viral culture. Serology, including neutralizing antibodies, was measured in blood specimens | ||
| 520 | |a Results: Fifteen participants, with a median age of 58 (range, 37‒77) years, were enrolled. Median duration of RT-PCR positivity from diagnosis was 18 days (interquartile range [IQR], 8‒24 days). Ten participants had at least one, for a total of 41, positive RT-PCR specimens ≥10 days after symptoms onset. Of these 41 specimens, 21 underwent viral culture; one (5%) was positive 14 days after symptom onset. Thirteen participants developed SARS-CoV-2-specific antibodies, 11 of which included neutralizing antibodies. RT-PCRs remained positive after seroconversion in eight participants and after detection of neutralizing antibodies in four participants; however, all of these samples were culture negative | ||
| 520 | |a Conclusions: Patients with ESKD on maintenance dialysis remained persistently and intermittently SARS-CoV-2-RT-PCR positive. However, of the 15 participants, only one had infectious virus, on day 14 after symptom onset. Most participants mounted an antibody response, including neutralizing antibodies. Participants continued having RT-PCR-positive results in the presence of SARS-CoV-2-specific antibodies, but without replication-competent virus detected | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ESRD | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a chronic kidney failure | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a end-stage renal disease | |
| 650 | 4 | |a infectiousness | |
| 650 | 4 | |a infectivity | |
| 650 | 4 | |a outpatients | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Korhonen, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Schatzman, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Gable, Paige |e verfasserin |4 aut | |
| 700 | 1 | |a Herzig, Carolyn |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Nicole E |e verfasserin |4 aut | |
| 700 | 1 | |a Beshearse, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Varela, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Sabour, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Lyons, Amanda K |e verfasserin |4 aut | |
| 700 | 1 | |a Overton, Rahsaan |e verfasserin |4 aut | |
| 700 | 1 | |a Hudson, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez-Romieu, Alfonso C |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Roman, Kaylin |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Soda, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Priti R |e verfasserin |4 aut | |
| 700 | 1 | |a Grate, Crystal |e verfasserin |4 aut | |
| 700 | 1 | |a Dalrymple, Lorien S |e verfasserin |4 aut | |
| 700 | 1 | |a Wingard, Rebecca L |e verfasserin |4 aut | |
| 700 | 1 | |a Thornburg, Natalie J |e verfasserin |4 aut | |
| 700 | 1 | |a Halpin, Alison S Laufer |e verfasserin |4 aut | |
| 700 | 1 | |a Folster, Jennifer M |e verfasserin |4 aut | |
| 700 | 1 | |a Tobin-D'Angelo, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Lea, Janice |e verfasserin |4 aut | |
| 700 | 1 | |a Apata, Ibironke |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, L Clifford |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Allison C |e verfasserin |4 aut | |
| 700 | 1 | |a Kutty, Preeta K |e verfasserin |4 aut | |
| 700 | 1 | |a Novosad, Shannon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney360 |d 2020 |g 2(2021), 12 vom: 30. Dez., Seite 1917-1927 |w (DE-627)NLM311083633 |x 2641-7650 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2021 |g number:12 |g day:30 |g month:12 |g pages:1917-1927 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.34067/KID.0004372021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2021 |e 12 |b 30 |c 12 |h 1917-1927 | ||